Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
about
Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteriaViridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniaeFluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal.Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniaeEvidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.Absence of tmRNA Has a Protective Effect against Fluoroquinolones in Streptococcus pneumoniaeChanges in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae.
P2860
Q33806725-938E1FC8-1EA3-4DB9-81D2-D6D6CB2D7127Q33980313-89975764-5EA6-410E-96F5-E6465470ACC6Q34035762-F11A27D8-1807-4DFD-8E8C-A6211AF3EB8EQ35102420-3CF6F9DD-3E32-4D15-872E-0F2507AEC2D7Q35880792-9DFC94BA-5223-448F-8BEB-8811E6693403Q36575147-C25B65C4-F048-4D3D-BA12-C0FF7D8D187EQ39473366-8CFBBB40-D2E7-4385-946B-E9545D41DA5DQ39476686-D0EFA735-9653-418B-858A-826D1BFB5FA4Q39477696-9403166D-4E17-4A9D-A834-980AB0FBF676Q39478343-78672A7C-8CE1-4DF3-893D-97D78EE4D6ADQ39653033-C8B6C691-7A50-456C-BF0A-53D82A3132C8Q40750740-6464E514-140B-4584-B113-7E1F953073C8Q41079092-4E1698C5-1292-4A42-B5D1-B4E6D231785DQ43069250-0B0E6BB8-F712-411C-A4EF-5AC520408769Q47138989-399AE4D4-80DD-4FDE-B719-E8D1DE05ECE8
P2860
Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Drug efflux and parC mutations ...... n viridans group streptococci.
@en
Drug efflux and parC mutations ...... n viridans group streptococci.
@nl
type
label
Drug efflux and parC mutations ...... n viridans group streptococci.
@en
Drug efflux and parC mutations ...... n viridans group streptococci.
@nl
prefLabel
Drug efflux and parC mutations ...... n viridans group streptococci.
@en
Drug efflux and parC mutations ...... n viridans group streptococci.
@nl
P2093
P2860
P356
P1476
Drug efflux and parC mutations ...... in viridans group streptococci
@en
P2093
J L Gómez-Garcés
M J Ferrándiz
P2860
P304
P356
10.1128/AAC.43.10.2520
P407
P577
1999-10-01T00:00:00Z